
Future Plans for Evaluating Spur Therapeutics’ FLT201
This is the second part of an interview with Reena Sharma, MD. For the first part, click here. Results from the phase 1/2 GALILEO-1 clinical trial (NCT05324943) evaluating Spur Therapeutics’ FLT201, an adeno-associated virus (AAV) vector-based gene …